Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma

J Gastroenterol Hepatol. 2000 Apr;15(4):422-30. doi: 10.1046/j.1440-1746.2000.02150.x.

Abstract

Background and methods: The plasminogen activation system plays a crucial role in the process of cancer invasion and metastasis. To evaluate the most effective factor in the invasion, metastasis and prognosis of hepatocellular carcinoma (HCC), we examined urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor (PAI)-1, PAI-2 and uPA activity by enzyme-linked immunosorbent assays (ELISA) in HCC tissues obtained from 46 patients. The results were compared with the patients' clinicopathological features and prognoses.

Results: Of the clinicopathological features, only histological portal involvement or intrahepatic metastasis, or both (INV), was significantly correlated to the disease-free survival rates (DFS; P < 0.05). The levels of uPA, PAI-1 and PAI-2 antigens were significantly associated with INV and histological grade. The DFS was not different, however, between cases with uPA, PAI-1 and PAI-2 values above and below the median. The high levels of uPA activity were closely related to INV (P < 0.001), and the activity gradually raised histological grades (P < 0.0001). The DFS was significantly different between patients with uPA activity below and above the median (0.70 ng/mL; P = 0.0092); it was also significantly different between such patients without INV (P < 0.05).

Conclusions: Urokinase-type plasminogen activator activity may be the most sensitive factor affecting HCC invasion in the plasminogen activation system and a strong predictor for the recurrence of HCC. We suggest that cases with uPA activity of more than 0.70 ng/mL should be carefully followed up for possible HCC recurrence.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antigens, Neoplasm / analysis
  • Biomarkers, Tumor / blood
  • Blotting, Western
  • Carcinoma, Hepatocellular / enzymology*
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / secondary
  • Disease-Free Survival
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Liver Neoplasms / enzymology*
  • Liver Neoplasms / pathology
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / enzymology
  • Neoplasm Recurrence, Local / pathology
  • Plasminogen Activator Inhibitor 1 / immunology
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Plasminogen Activator Inhibitor 2 / immunology
  • Plasminogen Activator Inhibitor 2 / metabolism
  • Urokinase-Type Plasminogen Activator / immunology
  • Urokinase-Type Plasminogen Activator / metabolism*

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Plasminogen Activator Inhibitor 1
  • Plasminogen Activator Inhibitor 2
  • Urokinase-Type Plasminogen Activator